微信小陈
微信小章
产品简介
购买须知
| 产品名称： | Panc 05.04 |
|---|---|
| 商品货号： | TS209425 |
| Organism： | Homo sapiens, human |
| Tissue： | pancreas |
| Cell Type： | Epithelial |
| Product Format： | frozen |
| Morphology： | epithelial |
| Culture Properties： | adherent |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | adenocarcinoma |
| Age： | 77 years adult |
| Gender： | female |
| Ethnicity： | White |
| Applications： | Panc 05.04 is a pancreatic adenocarcinoma epithelial cell line derived, in 1995, from a primary tumor removed from the head-of-the-pancreas of a female with pancreatic adenocarcinoma. The cell line exhibits a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Derivation： | Panc 05.04 is a pancreatic adenocarcinoma epithelial cell line derived, in 1995, from a primary tumor removed from the head-of-the-pancreas of a female with pancreatic adenocarcinoma. |
| Clinical Data： | 77 years adult female Panc 05.04 is a pancreatic adenocarcinoma epithelial cell line derived, in 1995, from a primary tumor removed from the head-of-the-pancreas of a female with pancreatic adenocarcinoma. White |
| Antigen Expression： | MHC class I +; MHC class II - Ref   Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602Blood type B; Rh+ |
| Oncogene： | K-ras +
RefJaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 |
| Genes Expressed： | cytokeratins 7 and 18,K-ras +,MHC class I +; MHC class II -,Blood type B; Rh+ |
| Cellular Products： | cytokeratins 7 and 18 Ref Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 |
| Tumorigenic： | Yes |
| Effects： | Yes, forms tumors in nude or SCID mice |
| Comments： | The cell line exhibits a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine.
The cells have a reported plating efficiency of 100%. Please note that the concentration ofxa0human recombinant insulin to bexa0added toxa0the complete growth medium for this cell line is 0.2 U/mL. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium:
|
| Subculturing： | Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
Subculture Ratio: 1:2 to 1:5 Medium Renewal: Add media once per week. Fluid change one to two times per week.
Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 13 in Culture of Animal Cells, a manual of Basic Technique by R. Ian Freshney,xa05th edition, published by Wiley-Liss, N.Y., 2005.
|
| Cryopreservation： | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37°C |
| Population Doubling Time： | 46 hrs |
| Name of Depositor： | EM Jaffee |
| Deposited As： | human |
| Year of Origin： | May 5, 1995 |
| References： | Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 |